Show results for
Refine by
Innate Immunity Suppliers In Europe
13 companies found
based inBrighton, UNITED KINGDOM
Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives with a focus on infection prevention. We have two exciting late-stage clinical assets and a range of earlier research programmes. Our ...
Destiny Pharma is working in collaboration with SporeGen Limited, a UK biotechnology company working exclusively on Bacillus and its applications, to co-develop SporeGen’s SPOR-COV™ product as a novel, preventive treatment for COVID-19. ...
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
based inBergen, NORWAY
Benchmark Genetics is a leader in aquaculture genetics, present in every major aquaculture market and for a wide range of species. Our five in-house breeding programmes are focusing on three main species: salmon, shrimp and tilapia. We are the ...
based inExeter, UNITED KINGDOM
Attomarker is a British company focused on nanophotonic biochemical testing. It was founded in 2008, and spun out from Professor Andrew Shaw’s research group at the University of Exeter. It has won numerous prestigious awards for innovation and been ...
based inTralee, IRELAND
BioAtlantis was established in 2004 and entered the crop biostimulant market in 2007 with stress mitigation as a central strategy. Stress is now recognised worldwide as affecting most life forms. It can be split into two main categories, abiotic and ...
based inShirley, NEW YORK (USA)
CD Bioparticles is an established drug delivery company which provides customized solutions for developing and producing new, biocompatible drug delivery systems. We specialize in a range of formulation and drug delivery technologies, from ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
based inParis, FRANCE
Enterome is pioneering the discovery and development of novel pharmaceuticals based on its unrivalled understanding of the interaction between the gut microbiome and the immune system – the Microbiome-Immunoinflammation Axis. Enterome is using this ...
based inLausanne, SWITZERLAND
AB2 Bio Ltd., located at the Innovation Park of the École Polytechnique Fédérale de Lausanne (EPFL), is a drug discovery and development company focused on developing “best in class” innovative therapies for the treatment of inflammatory diseases ...
based inToulouse, FRANCE
InvivoGen was founded in 1997 by scientists with technical expertise and creative excellence stemming from a longstanding history in microbiology. InvivoGen's unparalleled skill in microbial fermentation enables us to provide a wide range of ...
based inHeidelberg, GERMANY
We are a team of passionate, experienced individuals who work every day to improve the lives of patients. Led by an expert team of biotechnology and pharmaceutical professionals, we are united by one goal—to stop cancer from ever derailing patients’ ...
AFM24, an EGFR-directed ICE® (innate cell engager) molecule, represents a distinctive mechanism that engages innate immune cells by recruiting NK cells and macrophages to the site of the tumor ...
based inBalerna, SWITZERLAND
APR Applied Pharma Research s.a. (APR) is a Swiss Pharma company dedicated to providing patients suffering from rare diseases with innovative treatments that make a real difference in their life. Our focus as a Swiss global health care company is ...
based inUtrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...